Preview
Acute bacterial exacerbations of chronic bronchitis cause considerable morbidity and mortality, particularly in the elderly. Effective antimicrobial therapy results in fewer hospitalizations for respiratory failure and better resolution of symptoms. However, there is growing concern regarding treatment failures caused by resistant organisms. The authors therefore describe the activity of pharmacologic agents from different classes and indicate which ones may be considered primary treatment for this serious condition.
Additional information
Notes on contributors
Abraham Verghese
Abraham Verghese, MD Hassan M. Ismail, MD Dr Verghese (right) is professor of medicine and chief, sections of infectious disease and geriatrics, and Dr Ismail (left) is senior resident, department of internal medicine, Texas Tech University Regional Academic Health Center School of Medicine, El Paso.
Hassan M. Ismail
Abraham Verghese, MD Hassan M. Ismail, MD Dr Verghese (right) is professor of medicine and chief, sections of infectious disease and geriatrics, and Dr Ismail (left) is senior resident, department of internal medicine, Texas Tech University Regional Academic Health Center School of Medicine, El Paso.